A fully human antibody has slowed tumor growth and blocked the spread of aggressive prostate cancer in laboratory and mouse studies. Rather than attacking every part of a powerful cell-signaling pathway, the experimental drug targets one molecular cut that appears to help cancer cells become invasive and travel to lymph nodes.
The result is a promising early step, not yet a treatment patients can receive. The work was led by Maréne Landström at Umeå University, with Per Flodbring Larsson listed as first author, and it still needs wider safety testing before researchers can consider human use.
Why spread changes everything
Many prostate tumors grow slowly and may never threaten a patient’s life. What changes the picture? Cancer cells can escape the prostate and move into the lymph nodes or bones, a process called metastasis.
The study focused on metastatic castration-resistant prostate cancer. In plain terms, that means the disease has spread and keeps growing even after treatments lower or block the male hormones that once helped control it.
The researchers also examined tumor data from two patient groups, one with 158 people and another with 94. Higher activity of the gene behind the drug’s target was linked with poorer survival in both groups, supporting the idea that this pathway matters in aggressive disease.
How the antibody works
At the center of the study is TGF-beta, a signaling molecule that helps healthy tissues regulate growth, repair, and immune activity. In advanced cancer, however, parts of the same system can be hijacked to help tumor cells change shape, move, and invade.
An enzyme called ADAM17 can cut the TGF-beta type I receptor on a cancer cell. The released inner piece then travels to the cell’s control center and switches on programs linked to invasion and metastasis.
The antibody, known as mAbF11, attaches near that cut site and works like a protective cap. It prevents the damaging cut while preserving much of the pathway’s normal signaling, building on earlier research showing that the receptor helps prostate cancer cells migrate through surrounding tissue.
What the tests found
The team tested the antibody in human cancer cells and in mice carrying human prostate tumors in the prostate. In those preclinical models, treatment reduced tumor growth, cell invasion, and spread to nearby lymph nodes.
The effect became stronger at the higher tested dose levels. The antibody also lowered signs of rapid cell division and of a biological shift that makes cancer cells less anchored and more able to travel.
In a head-to-head mouse experiment, mAbF11 suppressed growth, invasion, and metastasis to a similar extent as docetaxel, a chemotherapy used for advanced prostate cancer. The chemotherapy arm was stopped after severe weight loss affected 8 of 16 mice.
In separate antibody tests, researchers reported no noticeable weight loss or measured changes in heart function or the nearby aorta.
Pelvic CT scan images illustrate the type of medical imaging used to evaluate advanced prostate cancer as researchers study new treatments designed to slow tumor growth and prevent metastasis.
Safety is still the big question
That safety signal is one reason the approach stands out. TGF-beta also supports normal work in the immune system, heart, and blood vessels, so blocking the entire pathway can create problems far beyond the tumor.
By targeting one cancer-linked cut instead, the antibody may limit that collateral damage. Mice cannot reveal every human reaction, however, and the animals in these experiments had weakened immune systems, so the absence of obvious side effects is encouraging rather than conclusive.
“This is a promising step forward, but several important stages remain,” she said. The treatment still needs additional safety studies and approval from regulators in Europe or the United States before it could reach patients.
What comes next
The researchers also tested the antibody in a preclinical model of triple-negative breast cancer and recorded fewer lung metastases. That does not establish a breast cancer treatment, but it gives the team a reason to investigate whether the same molecular weak spot appears in other solid tumors.
Development involved drug experts at SciLifeLab’s Drug Discovery and Development Platform, support from the Umeå Biotech Incubator, and financing from MetaCurUm Biotech AB. The paper reports that the study leader is a founder, shareholder, and board member of the company, an important disclosure because it develops therapies and biomarkers tied to this target.
The next milestone is not a pharmacy shelf but more preclinical work, especially deeper safety testing. For patients today, this is a promising research lead, not an approved drug.
The full study was published in Signal Transduction and Targeted Therapy.
